IL133508A - Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects containingan antitumor agent and an hydroximic acid derivative - Google Patents

Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects containingan antitumor agent and an hydroximic acid derivative

Info

Publication number
IL133508A
IL133508A IL13350898A IL13350898A IL133508A IL 133508 A IL133508 A IL 133508A IL 13350898 A IL13350898 A IL 13350898A IL 13350898 A IL13350898 A IL 13350898A IL 133508 A IL133508 A IL 133508A
Authority
IL
Israel
Prior art keywords
containingan
pharmaceutical composition
side effects
acid derivative
reduced side
Prior art date
Application number
IL13350898A
Other languages
English (en)
Other versions
IL133508A0 (en
Inventor
Balazs Sumegi
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of IL133508A0 publication Critical patent/IL133508A0/xx
Publication of IL133508A publication Critical patent/IL133508A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13350898A 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects containingan antitumor agent and an hydroximic acid derivative IL133508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative

Publications (2)

Publication Number Publication Date
IL133508A0 IL133508A0 (en) 2001-04-30
IL133508A true IL133508A (en) 2005-11-20

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13350898A IL133508A (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects containingan antitumor agent and an hydroximic acid derivative

Country Status (24)

Country Link
US (4) US6440998B1 (de)
EP (1) EP0993304B1 (de)
JP (1) JP2002508762A (de)
KR (1) KR20010020496A (de)
CN (1) CN1127984C (de)
AT (1) ATE235918T1 (de)
AU (1) AU735922B2 (de)
BR (1) BR9810312A (de)
CA (1) CA2294913C (de)
CZ (1) CZ298468B6 (de)
DE (1) DE69812949T2 (de)
DK (1) DK0993304T3 (de)
ES (1) ES2195344T3 (de)
HU (1) HU9701081D0 (de)
IL (1) IL133508A (de)
NO (1) NO322206B1 (de)
NZ (1) NZ502039A (de)
PL (1) PL191718B1 (de)
PT (1) PT993304E (de)
RU (2) RU2254129C2 (de)
SK (1) SK282877B6 (de)
TR (1) TR199903214T2 (de)
UA (1) UA64757C2 (de)
WO (1) WO1998058676A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
PL2368554T3 (pl) * 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
AU2008348717B2 (en) * 2007-10-30 2013-09-19 Trophos Novel composition for treating the side effects of anticancer treatments
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN116492347A (zh) * 2013-09-18 2023-07-28 华安医学股份有限公司 一种活化ampk的化合物及其用途
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
HUT74006A (en) * 1993-03-31 1996-10-28 Merck & Co Inc Hiv protease inhibitors in pharmaceutical combinations and pharmaceutical compns. contg. them
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
US6656955B2 (en) 2003-12-02
IL133508A0 (en) 2001-04-30
DE69812949D1 (de) 2003-05-08
US20020147213A1 (en) 2002-10-10
CA2294913C (en) 2008-12-16
US6440998B1 (en) 2002-08-27
WO1998058676A1 (en) 1998-12-30
NO996349L (no) 2000-02-23
DK0993304T3 (da) 2003-07-28
DE69812949T2 (de) 2004-02-05
ATE235918T1 (de) 2003-04-15
UA64757C2 (uk) 2004-03-15
NO996349D0 (no) 1999-12-20
RU2254129C2 (ru) 2005-06-20
EP0993304B1 (de) 2003-04-02
SK176499A3 (en) 2000-09-12
CN1263471A (zh) 2000-08-16
TR199903214T2 (xx) 2000-12-21
BR9810312A (pt) 2000-09-19
JP2002508762A (ja) 2002-03-19
AU7783798A (en) 1999-01-04
EP0993304A1 (de) 2000-04-19
US20030050345A1 (en) 2003-03-13
HK1029941A1 (en) 2001-04-20
PL191718B1 (pl) 2006-06-30
NZ502039A (en) 2002-03-28
US20030069270A1 (en) 2003-04-10
CZ298468B6 (cs) 2007-10-10
US6838469B2 (en) 2005-01-04
HU9701081D0 (en) 1997-08-28
SK282877B6 (sk) 2003-01-09
CN1127984C (zh) 2003-11-19
KR20010020496A (ko) 2001-03-15
PT993304E (pt) 2003-08-29
CA2294913A1 (en) 1998-12-30
RU2214238C2 (ru) 2003-10-20
NO322206B1 (no) 2006-08-28
CZ462599A3 (cs) 2000-05-17
US6720337B2 (en) 2004-04-13
AU735922B2 (en) 2001-07-19
ES2195344T3 (es) 2003-12-01
PL337719A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
IL133508A0 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and a hydroximic acid derivative
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
EP1731140A3 (de) Medizinische Aerosolformulierung
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
CA2416403A1 (en) A medicinal aerosol formulation
CA2037101A1 (en) Omeprazole Compositions Designed for Administration in Rectum
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
NZ502280A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
CA2308192A1 (en) 4'-c-ethynyl pyrimidine nucleoside compounds
HUP9700005A3 (en) 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
WO1998046576A3 (en) Halo-alkoxycarbonyl prodrugs
ZA966576B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them.
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
CA2347750A1 (en) Pharmaceutical composition containing decursin
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
TR200002766T2 (tr) 3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri
TR200002767T2 (tr) Makrolit LHRH Antagonistleri
HUP0202725A3 (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees